Herantis Pharma (OHEL:HRTIS) ROE % Adjusted to Book Value: 0.00% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OHEL:HRTIS Herantis Pharma PLC OHEL:HRTIS
26 GF Score
Price €1.63
! 3 Warning Signs
View Full Analysis

What is Herantis Pharma ROE % Adjusted to Book Value?

Herantis Pharma OHEL:HRTIS +4.49% 26 ROE % Adjusted to Book Value is 0.00% as of Dec. 2025. GuruFocus rates OHEL:HRTIS with a GF Score™ of 26/100. The stock has 3 warning signs investors should review.

Herantis Pharma's ROE % for the quarter that ended in Dec. 2025 was -22,419.67%. Herantis Pharma's PB Ratio for the quarter that ended in Dec. 2025 was N/A. Herantis Pharma's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 was N/A.

Herantis Pharma ROE % Adjusted to Book Value Related Terms

Herantis Pharma ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Herantis Pharma's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Herantis Pharma ROE % Adjusted to Book Value Chart

Herantis Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -11.92 0.00 1.78 0.00 0.00

Herantis Pharma Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 42.96 -9.66 0.00 -47.21 0.00

OHEL:HRTIS vs VRTX, REGN, RVMD: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Herantis Pharma's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Herantis Pharma ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Herantis Pharma's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Herantis Pharma's ROE % Adjusted to Book Value falls into.


OHEL:HRTIS
26GF Score
Herantis Pharma PLC OHEL:HRTIS
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Herantis Pharma ROE % Adjusted to Book Value Calculation

Herantis Pharma's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

Herantis Pharma's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-22,419.67% / N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of 0.00% mean?
Herantis Pharma (OHEL:HRTIS) has a ROE % Adjusted to Book Value of 0.00% as of Dec. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Herantis Pharma and its competitors.
Is Herantis Pharma's ROE % Adjusted to Book Value too high?
Herantis Pharma's current ROE % Adjusted to Book Value is 0.00%. Overall, Herantis Pharma has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Herantis Pharma's ROE % Adjusted to Book Value compare to VRTX and REGN?
Herantis Pharma's ROE % Adjusted to Book Value of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Herantis Pharma and its competitors. Herantis Pharma's current ROE % Adjusted to Book Value is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Herantis Pharma stock overvalued right now?
Herantis Pharma (OHEL:HRTIS) has a current ROE % Adjusted to Book Value of 0.00%. The current ROE % Adjusted to Book Value is 0.00%. Herantis Pharma's overall GF Score™ is 26/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Herantis Pharma (OHEL:HRTIS), the current ROE % Adjusted to Book Value is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Herantis Pharma Business Description

Address Bertel Jungin Aukio 1, Espoo, FIN, 02600
Herantis Pharma PLC is a biotech company developing disease-modifying therapies for Parkinsons disease. The company's current development program focuses solely on HER-096, which is a peptidomimetic molecule designed to retain the biological activity of the neuroprotective CDNF protein.
26GF Score

Get the complete analysis for OHEL:HRTIS

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.63
Price